@FiercePharma: ICYMI earlier: Dendreon's debt plans could leave stockholders in the lurch. Article | Follow @FiercePharma
@EricPFierce: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Story | Follow @EricPFierce
@CarlyHFierce: ICYMI earlier: BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt. More | Follow @CarlyHFierce
> A new study found commonly used heart med digoxin may shorten the lives of patients with atrial fibrillation. Story (sub. req.)
> Sun Pharma's first-quarter results topped analyst estimates, pushing shares upward. Report
> Health Canada has OK'd GlaxoSmithKline's ($GSK) plan to address problems at its Quebec-based flu vaccine plant. More
Medical Device News
@FierceMedDev: Private hospitals in China are a priority for med tech Mindray. Story | Follow @FierceMedDev
@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence
@VarunSaxena2: In a 1st, CMS proposed to cover @ExactSciences Cologuard Dx upon FDA approval, so it should get reimbursement faster. FierceDiagnostics story | Follow @VarunSaxena2
@EmilyWFierce: Lung transplant device wins FDA approval, holds potential for critically ill patients with cystic fibrosis. More from the NYT | Follow @EmilyWFierce
> Exact Sciences bags FDA approval and proposed CMS coverage for colorectal cancer screening test. Story
> FDA approves lung preservation device. Item
> Abbott wins Medicare coverage, new tech add-on payments for MitraClip cardiology device. Report
Biotech News
@FierceBiotech: In-depth @Reuters piece on government's move to roll back oversight on biosecurity research. Article | Follow @FierceBiotech
@DamianFierce: ICYMI: Digging into the FDA's priority review voucher. Who's willing to pay big for one? Story | Follow @DamianFierce
@EmilyMFierce: Using experimental drugs and vaccines against Ebola is ethical, WHO panel says. Report from Science | Follow @EmilyMFierce
> Ear disease biotech Otonomy bags $100M in a booming IPO. Report
> When will Merck KGaA take the M&A plunge? More
> AstraZeneca clears some key PhIII hurdles with lesinurad gout combos. News
> Celltrion targets J&J's Remicade as biosimilars loom in the U.S. Story
Drug Delivery News
> Arrowhead updates TheStreet on clinical trial results of RNAi candidate for hepatitis B. Story
> Can insect venom be harnessed to fight cancer? Article
> Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. More
> pH-sensing capsules that deliver optimal quantity of insulin under development. Story
> Oraya receives NIH grant to study use of its novel eye radiation tech against cancer. Article
Diagnostics News
> Novartis, LabCorp and more back Seventh Sense Biosystems' latest financing. Editor's corner
> Northern Ireland outfit advances a rapid but inexpensive heart attack test. Report
> GE Healthcare vet to take on Biocept's Dx reimbursement strategy. More
> Exact Sciences wins FDA approval and more for next-gen colon cancer Dx. Story
> Oxford Immunotec grabs remnants of Colorado rival for a bargain. Article
Pharma Marketing News
> Bye-bye, Incivek: Sovaldi forces Vertex drug off hep C market. Item
> BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt. Article
> Communiqué to sales reps: With today's docs, it's the medium and the message. More
> There's room for more parents, docs on Merck's Gardasil bandwagon. Story
> MannKind recruits Sanofi to hawk Afrezza in $925M marketing deal. Article
And Finally... Canada's government will donate doses of an experimental Ebola vaccine to the World Health Organization. More